Clinical trials: Prostate Cancer Stage
Prostate Cancer
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy
The participants of this study had Prostate Cancer. Prostate cancer is cancer that occurs in the prostate, a small gland in the male reproductive system.
- Trial name
- REAL6T (NCT05759273)
- Where
- 13 sites in Italy
- Volunteers
- 167 people
- Sponsor
- Ipsen
Prostatic Neoplasms, Cancer of the Prostate
Hemi-Ablative Prostate Brachytherapy
This clinical study will evaluate side effects, quality of life and cancer control in patients with prostate cancer diagnosed on only one side of the prostate gland.
- Trial name
- HAPpy (NCT02632669)
- Testing
- Hemigland focal LDR brachytherapy
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01093183
- Testing
- lenalidomide, cyclophosphamide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Nebraska
Prostate Cancer
Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer
RATIONALE: Diagnostic procedures, such as technetium Tc 99m demobesin-4 followed by single-photon emission computer tomography, CT scan, and MRI, may help find prostate cancer and learn the extent of disease.
- Trial name
- NCT00989105
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Cancer Research UK
Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- Trial name
- PSMA SBRT-SIB (NCT04402151)
- Testing
- PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
- Trial name
- NCT01317641
- Testing
- ODM-201
- Where
- 23 sites in United States, Czechia and 4 more
- Volunteers
- 136 people
- Sponsor
- Orion Corporation, Orion Pharma
Aggressive Variant Prostate Carcinoma
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
This is a multi-center single arm phase II study to evaluate the antitumor activity of zanzalintinib 60mg orally (PO) once daily in subjects with AVPC.
- Trial name
- NAPOLEON (NCT07218666)
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Deepak Kilari
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04489719
- Testing
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
High-risk Prostate Cancer
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
This study tests a new treatment for men with high-risk prostate cancer who can't have surgery. The treatment combines three experimental drugs and radiation therapy.
- Trial name
- NCT06765954
- Testing
- N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells)
- Sponsor
- ImmunityBio, Inc.
Prostate Cancer
Multimodality Phase II Study in Prostate Cancer
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy…
- Trial name
- NCT00734851
- Testing
- Docetaxel, Sunitinib, EBXRT
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well metformin hydrochloride works compared to placebo in treating patients with prostate cancer undergoing surgery. Metformin hydrochloride may make some enzymes active.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01433913
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without…
- Trial name
- NCT00776594
- Testing
- Androgen Deprivation Therapy, bicalutamide, bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors
This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily.
- Trial name
- POSTPONE (NCT07226713)
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Prostate Cancer
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003124
- Testing
- flutamide, leuprolide acetate, radiation therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Prostate Cancer
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045227
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Prostate Cancer
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
- Trial name
- NCT06490328
- Testing
- DKF-MA102
- Where
- 8 sites in South Korea
- Volunteers
- 161 people
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Stage I Prostate Cancer, Stage IIA Prostate Cancer
Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery
This randomized pilot phase II trial studies the side effects and how well defined green tea catechin extract works in treating patients with localized prostate cancer undergoing surgery.
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01340599
- Testing
- defined green tea catechin extract, immunohistochemistry staining method, immunoenzyme technique
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Prostate Cancer Active Surveillance Metformin Trial
To determine whether the use of metformin in patients with low-risk prostate cancer can delay progression to clinically significant prostate cancer.
- Trial name
- NCT01733836
- Testing
- Metformin
- Where
- Canada
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.